HONG KONG Amgen Inc. and Simcere Pharmaceutical Group have entered into an agreement to develop and commercialize four biosimilars for the Chinese market.
HONG KONG – Singapore startup Enleofen Bio Pte Ltd. has acquired the licensing rights of a breakthrough discovery by the Duke-National University of Singapore (NUS) Medical School and the National Heart Centre Singapore (NHCS) in cardiovascular fibrosis drivers.
HONG KONG – CSPC Pharmaceutical Group Ltd. received orphan drug status for its mitoxantrone liposome product from the FDA, though the Chinese company warned that much work remains to get the phase II-stage drug across the finish line in the initial U.S. and China markets.
HONG KONG – CSPC Pharmaceutical Group Ltd. received orphan drug status for its mitoxantrone liposome product from the FDA, though the Chinese company warned that much work remains to get the phase II-stage drug across the finish line in the initial U.S. and China markets.
HONG KONG – Singapore startup Enleofen Bio Pte Ltd. has acquired the licensing rights of a breakthrough discovery by the Duke-National University of Singapore (NUS) Medical School and the National Heart Centre Singapore (NHCS) in cardiovascular fibrosis drivers.
HONG KONG – Shanghai Fosun Pharmaceutical Group Co. Ltd. has made progress on its proposed purchase of the majority stake in India's Gland Pharma Ltd., with a recent amendment stating it would acquire 74 percent of the interest in the Hyderabad-based pharmaceutical company for $1.09 billion, instead of the original proposed 86 percent for $1.26 billion.
HONG KONG – Chinese biotech company Harbour Biomed Therapeutics Ltd. has entered a collaboration and licensing agreement with South Korea's Hanall Biopharma Co. Ltd. for novel biologics. Under the agreement, Harbour, of Shanghai, will have the rights to develop, manufacture and commercialize HL-161 and HL-036 for the Greater China market, which includes the territories of Hong Kong, Macau and Taiwan.
